| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
1 Institut Gustave Roussy, Villejuif, France; 2 The University of Colorado Cancer Center, Denver, Colorado; 3 Eli Lilly and Company, Indianapolis, Indiana; 4 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; and 5 Eli Lilly and Company, St. Cloud, France
Purpose: Cisplatin is one of the most active agents for the treatment of non-small cell lung cancer (NSCLC). It is also known for significant toxicity, which makes it unsuitable for certain patients. Our purpose was to evaluate the efficacy and toxicity of a promising cisplatin-free combination, gemcitabine plus pemetrexed, in NSCLC.
Experimental Design: Chemo-naive patients with inoperable NSCLC were eligible for this study. Gemcitabine (1250 mg/m2) was given intravenously on days 1 and 8, followed by intravenous pemetrexed (500 mg/m2) on day 8. After inclusion of 13 patients, folic acid and vitamin B12 supplementation was added to lower pemetrexed-induced toxicity. Quality of life was assessed with the Lung Cancer Symptom Scale.
Results: Sixty patients enrolled; 58 were evaluable for response. All patients had a World Health Organization performance status of 0 or 1. Eighty-seven percent had stage IV disease. Nine patients had a confirmed partial response [overall response rate, 15.5%; 95% confidence interval (CI), 7.3–27.4%]. Twenty-nine (50.0%) patients had stable disease. Median overall survival was 10.1 months (95% CI, 7.9–13.0 months), with a 1- and 2-year overall survival of 42.6% (95% CI, 30.0–55.3%) and 18.5% (95% CI, 7.9–29.1%). Median progression-free survival was 5.0 months. Median response duration was 3.3 months. There were no deaths attributed to treatment. Common Toxicity Criteria grade 3/4 toxicities were neutropenia (61.7%), febrile neutropenia (16.7%), fatigue (23.3%), and elevations of aspartate aminotransferase (15.0%) and alanine aminotransferase (20.0%).
Conclusions: This combination had good tolerance and achieved promising overall survival with extended 1- and 2-year survival rates. This cisplatin-free regimen warrants further evaluation in randomized trials.
This article has been cited by other articles:
|
|
 |
|
  H. L. West, H. A. Wakelee, M. C. Perry, R. J. Belt, R. Chen, and C. Obasaju Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial Ann. Onc., May 1, 2009; 20(5): 850 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Simon, C. F. Verschraegen, P. A. Janne, C. J. Langer, A. Dowlati, S. M. Gadgeel, K. Kelly, G. P. Kalemkerian, A. M. Traynor, G. Peng, et al. Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial J. Clin. Oncol., July 20, 2008; 26(21): 3567 - 3572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Y. Seiwert, P. P. Connell, A. M. Mauer, P. C. Hoffman, C. M. George, L. Szeto, R. Salgia, K. E. Posther, B. Nguyen, D. J. Haraf, et al. A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer Clin. Cancer Res., January 15, 2007; 13(2): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hendricksen, P. M.J. Moonen, A. G. van der Heijden, J. Molkenboer-Kuenen, C. A. Hulsbergen-van de Kaa, and J. A. Witjes Potential and Toxicity of Intravesical Pemetrexed: a Preclinical Study in Pigs Clin. Cancer Res., April 15, 2006; 12(8): 2597 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. X. Ma, S. Nair, S. Thomas, S. J. Mandrekar, D. A. Nikcevich, K. M. Rowland, T. R. Fitch, H. E. Windschitl, S. L. Hillman, S. E. Schild, et al. Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5929 - 5937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dubey and J. H. Schiller Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab Oncologist, April 1, 2005; 10(4): 282 - 291. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
